Urinary Ephrin-B1 Marker for Early Nephrotic Syndrome Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for nephrotic syndrome lack effective markers for early detection and progression monitoring, particularly focusing on the role of Ephrin-B1 in urine samples, which is crucial for timely intervention and reducing medical costs associated with kidney failure.
Innovation Solution
Utilizing Ephrin-B1 as a marker in urine samples for diagnosing nephrotic syndrome through methods like Western blotting, ELISA, and RT-PCR to measure its expression levels, enabling early detection and monitoring of disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for nephrotic syndrome, then diagnosis can be performed, but early detection and progression monitoring are insufficient
Solution Approach 1:
The patent applies preliminary action by detecting Ephrin-B1 expression changes before clinical nephrotic syndrome symptoms fully manifest. The method identifies early molecular markers (Ephrin-B1 downregulation) in urine samples during the pathogenesis period immediately before proteinuria onset, enabling early intervention before the disease progresses to require dialysis therapy
Solution Approach 2:
The patent replaces conventional mechanical/physical diagnostic methods with molecular biology techniques. Instead of relying on traditional urine protein quantification alone, the invention uses RT-PCR to detect Ephrin-B1 mRNA expression levels, substituting molecular-level detection for conventional clinical chemistry approaches
2Reliability
If kidney failure treatment is provided, then patient survival is maintained, but medical costs become extremely high
Solution Approach 1:
The patent enables preliminary intervention by detecting Ephrin-B1 expression changes before kidney failure occurs. By identifying patients at risk during the early pathogenesis period and implementing preventive treatments to suppress proteinuria, the system avoids the need for expensive dialysis therapy while maintaining patient survival
Solution Approach 2:
The patent establishes a feedback mechanism for monitoring disease progression. By regularly measuring Ephrin-B1 expression levels in urine samples, clinicians can assess whether proteinuria suppression therapy is effective and adjust treatment accordingly, preventing progression to kidney failure and avoiding costly end-stage interventions
3Reliability
If proteinuria suppression therapy is developed, then kidney disease progression is prevented, but diagnostic markers are needed
Solution Approach 1:
The patent extracts the specific molecular marker (Ephrin-B1) from the complex system of kidney disease pathogenesis. By focusing on this single key molecule whose expression changes precede proteinuria onset, the invention simplifies the diagnostic approach while maintaining high reliability for predicting disease progression and monitoring therapy response
Data Source
Figure 1~3
Figure 4~7
AI summary
The present invention provides use of an Ephrin-B as a marker for assisting in the diagnosis of nephrotic syndrome, a method for examining nephrotic syndrome comprising measuring the expression level of an Ephrin-B in the urine of a subject, and a diagnostic reagent for nephrotic syndrome comprising a substance that specifically binds to an Ephrin-B.